Natco Pharma wins on the launch of Everolimus 10 mg on the US market
Natco Pharma rose 1.90% to Rs 908 after the drug maker launched its Everolimus 10 mg tablets in the US market.
Everolimus is a generic version of Afinitor tablets, used to treat certain types of cancer, tumors and seizures.
According to industry sales data, the 10 mg strength of Infinitor generated annual sales of $ 392 million in the twelve months ending July 2021.
On a consolidated basis, Natco Pharma’s net profit fell 38.6% to Rs 75 crore on a 27.2% drop in net sales to Rs 410.30 crore in the first quarter of June 2021 compared to the first quarter June 2020.
Natco Pharma manufactures a full line of branded and generic dosage forms, bulk actives and intermediates for the Indian and international markets.
Powered by Capital Market – Live News
(This story was not edited by Business Standard staff and is auto-generated from a syndicated feed.)